STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMNM
  4. [Form 4] Immunome Inc. Insider Trading Activity

Immunome (IMNM) CBO sells 90,616 shares via 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Immunome Inc.’s Chief Business Officer Kinney Horn reported option exercises and related stock sales. On August 4, 2026, Horn exercised employee stock options for an aggregate 90,616 shares of common stock at exercise prices of $12.92 and $10.60 per share, then reported selling 90,616 shares of common stock at a weighted average price of $25.09 per share, within a range of $25.00–$25.295, pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Positive

  • None.

Negative

  • None.
Insider Horn Kinney
Role CHIEF BUSINESS OFFICER
Sold 90,616 shs ($2.27M)
Approx. gross sale proceeds $2.27M
Approx. exercise cost $1.08M
Approx. pre-tax spread $1.20M
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) F3 50,366 $0.00 $0.00
Exercise Employee Stock Option (right to buy) F4 40,250 $0.00 $0.00
Exercise Common Stock 50,366 $12.92 $651K
Exercise Common Stock 40,250 $10.60 $427K
Sale Common Stock F1, F2 90,616 $25.09 $2.27M
Holdings After Transaction: Employee Stock Option (right to buy) — 199,292 shares (Direct); Common Stock — 0 shares (Direct)
Footnotes (4)
  1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
  2. F2. The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. F3. 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
  4. F4. 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.
Options exercised at $12.92 50,366 shares Employee stock options exercised on August 4, 2026 at $12.92 per share
Options exercised at $10.60 40,250 shares Employee stock options exercised on August 4, 2026 at $10.60 per share
Shares sold 90,616 shares Common stock sale reported on August 4, 2026
Weighted average sale price $25.09 per share Sale price for 90,616 common shares, range $25.00–$25.295
Option strike price 1 $12.92 per share Employee Stock Option (right to buy) expiring August 8, 2034
Option strike price 2 $10.60 per share Employee Stock Option (right to buy) expiring July 28, 2035
Rule 10b5-1 trading plan regulatory
"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (right to buy) financial
"Security title listed as Employee Stock Option (right to buy)"
weighted average sale price financial
"The weighted average sale price for the transaction report was $25.09"
vested financial
"25% of the shares subject to the option vested on August 9, 2025"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did Immunome (IMNM) report for Kinney Horn on August 4, 2026?
Immunome’s Chief Business Officer Kinney Horn exercised employee stock options for 90,616 shares and reported selling 90,616 shares of common stock on August 4, 2026, combining option exercises with a same-date share sale.

How many Immunome (IMNM) shares did Kinney Horn sell and at what price?
Kinney Horn reported selling 90,616 shares of Immunome common stock at a weighted average price of $25.09 per share, with individual sale prices ranging between $25.00 and $25.295, as disclosed in the Form 4 footnotes.

What stock options did Kinney Horn exercise in the Immunome (IMNM) Form 4 filing?
Horn exercised employee stock options covering 50,366 shares at an exercise price of $12.92 per share and 40,250 shares at $10.60 per share, resulting in acquisition of the same number of Immunome common shares.

Were Kinney Horn’s Immunome (IMNM) stock sales under a Rule 10b5-1 plan?
Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by Kinney Horn on March 30, 2026, and the Rule 10b5-1 checkbox is affirmed at the document level.

What are the vesting terms of Kinney Horn’s Immunome (IMNM) stock options mentioned in the Form 4?
One option grant vests 25% on August 9, 2025 with remaining shares vesting monthly over three years. Another vests 25% on July 29, 2026, with the balance also vesting monthly over three years.

What are the expiration dates of the Immunome (IMNM) stock options exercised by Kinney Horn?
The employee stock options exercised by Kinney Horn are scheduled to expire on August 8, 2034 for the $12.92 strike options and on July 28, 2035 for the $10.60 strike options, if not exercised earlier.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Horn Kinney
(Last)(First)(Middle)
C/O IMMUNOME, INC.
18702 N. CREEK PARKWAY, SUITE 100
(Street)
BOTHELL WASHINGTON 98011
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF BUSINESS OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/04/2026M50,366A$12.9250,366D
Common Stock08/04/2026M40,250A$10.690,616D
Common Stock08/04/2026S(1)90,616D$25.09(2)0D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$12.9208/04/2026M50,366 (3)08/08/2034Common Stock50,366$078,542D
Employee Stock Option (right to buy)$10.608/04/2026M40,250 (4)07/28/2035Common Stock40,250$0120,750D
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
2. The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
4. 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.
/s/ Sandra G. Stoneman, Attorney-in-Fact08/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR